Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2020-01-06 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Regulatory Filings Classification · 1% confidence The document is a press release dated January 6, 2020, announcing 'Encouraging Data' from a clinical trial extension study (PLEO-CMT-FU) for a drug candidate (PXT3003). It details preliminary efficacy and safety results, references previous study phases (Phase 3), and includes quotes from the CEO and external experts. Crucially, it announces a conference call to discuss these results and mentions that accompanying slides will be available on the company website. This structure—announcing key results and scheduling a call to discuss them—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since the content is focused on clinical trial results rather than quarterly financial performance highlights, and it is a formal announcement of new information, it fits best as an Earnings Release (ER) if we interpret 'Earnings' broadly to include major operational milestones for a clinical-stage biotech, or potentially a Regulatory Filing (RNS) if it were a required filing. However, given the structure of announcing key data points and scheduling a call, 'ER' (Earnings Release) is often used for major operational updates in this context, though 'RNS' (Regulatory Filings/General Announcement) is also plausible. Since it is a press release announcing clinical data and scheduling a call, and it is not a full report (like 10-K or IR), it is most closely aligned with the function of an Earnings Release (ER) which serves as the initial public announcement of significant period-specific news, or RNS as a general announcement. Given the context of clinical data release, ER is a strong candidate, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate the definitions. It is not a Call Transcript (CT), nor an Investor Presentation (IP). It is an announcement of results, not the full report itself. It is most similar to an Earnings Release (ER) which announces period results/highlights. I will classify it as ER based on the structure of announcing key findings and scheduling a follow-up call, which mirrors how earnings are often announced.
2020-01-06 English
Pharnext annonce des résultats encourageants de l'étude d'extension de Phase 3 en ouvert de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
Earnings Release Classification · 1% confidence The document is titled with a headline announcing clinical study results ("Pharnext annonce des résultats encourageants de l'étude d'extension de Phase 3 en ouvert de PXT3003...") and contains key financial/clinical highlights, followed by details about the study design and future regulatory steps. It explicitly states it is a "Communiqué de Presse" (Press Release) at the bottom of several pages. This format, announcing key periodic results (clinical trial updates, which often accompany or precede earnings releases), strongly suggests an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial results rather than quarterly financial performance highlights, and it is a formal press release, it fits best under the 'Earnings Release' category (ER) as the primary vehicle for disseminating material periodic operational/clinical news to the market, or potentially 'Regulatory Filings' (RNS) if it were less structured. Given the structure announcing key findings and scheduling a conference call to discuss them, ER is the most appropriate fit among the specific options, as it serves the function of an initial results announcement. FY 2020
2020-01-06 French
Pharnext establishes an equity line facility with Kepler Cheuvreux
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "*Press Release*" and announces a specific corporate action: the establishment of an equity line facility with Kepler Cheuvreux to enhance financial flexibility. This type of announcement, detailing financing arrangements, capital structure adjustments, or fundraising activities, aligns directly with the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an interim report (IR), or a simple earnings release (ER). Since it is a detailed announcement of a financing event, CAP is the most appropriate classification.
2019-11-19 English
Pharnext met en place une ligne de financement en fonds propres avec Kepler Cheuvreux
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 19, 2019, announcing that Pharnext has established a new equity financing line with Kepler Cheuvreux. The core subject is a financing activity aimed at increasing financial flexibility and liquidity. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but a specific announcement about securing capital.
2019-11-19 French
Pharnext announces 2019 half-year results
Earnings Release Classification · 1% confidence The document is explicitly titled "Pharnext announces 2019 half-year results" and contains a "FINANCIAL INFORMATION SUMMARY" table with key figures for the first half of 2019 (end of June). This structure, focusing on comprehensive financial data for a period shorter than a year, aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is presented as a press release, the content is the detailed financial summary itself, not just an announcement of its publication (which would be RPA/RNS). It is too detailed to be just an Earnings Release (ER) which typically contains only key highlights. Therefore, the classification is IR. H1 2019
2019-10-16 English
Pharnext annonce ses résultats financiers semestriels 2019
Earnings Release Classification · 1% confidence The document is titled "Pharnext annonce ses résultats financiers semestriels 2019" (Pharnext announces its 2019 half-year financial results). It contains a detailed table of synthetic financial information (income statement elements, cash flows) for the first half of 2019, comparing it to 2018, and provides management commentary on these results. This content structure is characteristic of a comprehensive report covering a period shorter than a full year, specifically a half-year report. This aligns directly with the definition of an Interim / Quarterly Report (Code: IR). It is not just an Earnings Release (ER) as it contains extensive financial tables and detailed explanations, nor is it the full Annual Report (10-K). H1 2019
2019-10-16 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.